Evidence map›Paper›PMID 38258053›Full record

ArticlePharmaceutics2023

Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid.

Javier Santamaría-Aguirre, Daniela Jacho, Miguel A Méndez, Ana Poveda, Javier Carrión, Mónica L Fanarraga

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. EXCLI journal · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Javier Santamaría-AguirreDepartamento de Biología Molecular, Universidad de Cantabria, 39011 Santander, Spain.ORCID 0000-0002-1683-5737
Daniela JachoFacultad de Ciencias Químicas (FCQ), Universidad Central del Ecuador, Quito 170521, Ecuador.
Miguel A MéndezDepartamento de Ingeniería Química, Instituto de Simulación Computacional (ISC-USFQ), Universidad San Francisco de Quito USFQ, Quito 170157, Ecuador.ORCID 0000-0001-9281-2644
Ana PovedaGrupo de Investigación en Biodiversidad, Zoonosis y Salud Pública (GIBCIZ), Instituto de Investigación en Zoonosis (CIZ), Facultad de Ciencias Químicas (FCQ), Universidad Central del Ecuador, Quito 170521, Ecuador.ORCID 0000-0003-1505-1372
Javier CarriónGrupo ICPVet, Departamento Sanidad Animal, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0001-7486-4942
Mónica L FanarragaDepartamento de Biología Molecular, Universidad de Cantabria, 39011 Santander, Spain.ORCID 0000-0003-4754-311X
Central University of Ecuador · ECUniversidad de Cantabria · ESUniversidad Complutense de Madrid · ESUniversidad San Francisco de Quito · EC

Funding

Agencia Estatal de Investigación TED2021-129248B-I00European Regional Development Fund TED2021-129248B-I00Instituto de Investigación Marqués de Valdecilla INNVAL 17/11MICIN/AEI/ 1013039/501100011033 RED2022-134560-T
6 · The paper itself

Abstract

Leishmaniasis, a zoonotic parasitic disease transmitted by infected sandflies, impacts nearly 1 million people yearly and is endemic in many countries across Asia, Africa, the Americas, and the Mediterranean; despite this, it remains a neglected disease with limited effective treatments, particularly in impoverished communities with limited access to healthcare. This study aims to repurpose approved drugs for an affordable leishmaniasis treatment. After the screening of potential drug candidates by reviewing databases and utilizing molecular docking analysis, delamanid was chosen to be incorporated into solid lipid nanoparticles (SLNPs). Both in cellulo and in vivo tests confirmed the successful payload release within macrophages and through the epidermis following topical application on murine skin. The evaluation of macrophages infected with

Indexed as

benzimidazolesfluoroquinolonenanomedicineneglectedtrypanosomatidzoonosis

Identifiers

PMID38258053
PMCPMC10818933
OpenAlexW4390267598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.